Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2804-2811

  Nakayama, Kentaro ^b   Kanzaki, Atsuko ^a   Terada, Kunihiko ^d   Mutoh, Masato ^e   Ogawa, Kenji ^f   Sugiyama, Toshihiro ^d   Takenoshita, Seiichi ^a   Itoh, Kiyoshi ^f   Yaegashi, Nobuo ^f   Miyazaki, Kohji ^b   Neamati, Nouri ^c   Takebayashi, Yuji ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TORAY INDUSTRIES INC   (Japan)

^f TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE (COPPER); CISPLATIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BIOLOGICAL TRANSPORT; CARCINOMA; CATION TRANSPORT PROTEINS; CISPLATIN; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11144354318     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0454     Document Type: Article

References (35)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Boente MP, Schilder R, Ozols RF. Gynecologic cancers. Cancer Chemother Biol Response Modif 1997;17:536-61.
3. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59:8-13.
4. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells [published erratum appears in Proc Natl Acad Sci USA 1999;96(5):2569]. Proc Natl Acad Sci USA 1998;95:15665-70.
5. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells [published erratum appears in Proc Natl Acad Sci USA 1999;96(5):2569]. Proc Natl Acad Sci USA 1998;95:15665-70.
6. Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59:4237-41.
7. Volk EL, Rohde K, Rhee M, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux [in process citation]. Cancer Res 2000;60:3514-21.
8. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46.
9. Harris ED, Quian Y, Tiffany-Castiglioni E, Lacy AR, Reddy MC. Functional analysis of copper homeostasis in cell culture models: a new perspective on internal copper transport. Am J Clin Nutr 1998;67 (Suppl):988-95S.
10. Petrukhin K, Lutsenko S, Chernov I, et al. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 1994;3:1647-56.
11. Komatsu M, Sumizawa T, Mutoh M, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000;60:1312-6.
12. Terada K, Schilsky ML, Miura N, et al. ATP7B (WND) protein. Int J Biochem Cell Biol 1998;30:1063-7.
13. Solioz M, Vulpe C. CPx-type ATPases: a class of P-type ATPases that pump heavy metals. Trends Biochem Sci 1996;21:237-41.
14. Gupta A, Matsui K, Lo JF, et al. Molecular basis for resistance to silver cations in Salmonella. Nat Med 1999;5:183-8.
15. Roberts EA, Cox DW: Wilson disease. Baillieres Clin Gastroenterol 1998;12:237-56.
16. Iida M, Terada K, Sambongi Y, et al. Analysis of functional domains of Wilson disease protein (ATP7B) in Saccharomyces cerevisiae. FEBS Lett 1998;428:281-5.
17. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
18. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
19. Goff BA, Shy K, Greer BE, et al. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor α in epithelial ovarian cancer. Eur J Gynaecol Oncol 1996;17:487-92.
20. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-5.
21. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
22. Vasey PA, Jones NA, Jenkins S, et al. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996;50:1536-40.
23. Buttitta F, Marchetti A, Gadducci A, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5.
24. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
25. Lin X, Ramamurthi K, Mishima M, et al. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001;61:1508-16.
26. Green JA, Robertson LJ, Campbell IR, et al. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995;19:151-5.
27. Diebold J, Baretton G, Felchner M, et al. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-9.
28. Klemi PJ, Pylkkanen L, Kiilholma P, et al. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
29. Henriksen R, Strang P, Wilander E, et al. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-6.
30. Yang XL, Miura N, Kawarada Y, et al. Two forms of Wilson disease protein produced by alternative splicing are localized in distinct cellular compartments. Biochem J 1997;326:897-902.
31. Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
32. Nakayama K, Konno M, Kanzaki A, et al. Allelotype analysis of gallbladder carcinoma associated with anomalous junction of pancreaticobiliary duct. Cancer Lett 2001;166:135-41.
33. Weber-Hall S, Anderson J, McManus A, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 1996;56:3220-4.
34. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
35. Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst (Bethesda) 1996;88:173-82.